Search

The use of artificial intelligence (AI) to create various forms of media raises interesting legal issues relating to the protection of intellectual property. Generative AI is being used to create songs that have vocals and other characteristics that mimic the sound and style of famous musicians. In...

PCI, in partnership with Penn Medicine, is pleased to co-host a commercialization speaker series geared toward Penn Medicine faculty, researchers and students. Each session will feature an expert guest speaker as well as time for questions and discussion. The first session will discuss the latest...

​The use of artificial intelligence (AI) to create various forms of media raises interesting legal issues relating to the protection of intellectual property. Generative AI is being used to create songs that have vocals and other characteristics that mimic the sound and style of famous musicians...

Francelina Perdomo Klukosky brings extensive experience as an intellectual property attorney to her new role as counsel in the firm. Ms. Perdomo Klukosky focuses on both litigation and transactions for clients in the sports and entertainment industries. She is resident in the New York office. Ms...

​The use of artificial intelligence (AI) to generate creative works raises interesting legal challenges to the protection of intellectual property. The plain language of the Copyright Act presents obstacles to artists who may use generative AI as part of their creative process. The U.S. Copyright...

On February 28, 2023, the Federal Trade Commission (“FTC”) and Consumer Financial Protection Bureau (“CFPB”) issued a Request for Information (“RFI”) seeking public comment on background screening issues affecting rental housing applicants and tenants in the United States. The 10-page RFI, which the...

The use of artificial intelligence (AI) to create works of art creates interesting legal challenges to the protection of intellectual property. A copyright infringement class action lawsuit has been filed against providers of AI software that is used to generate visual works of art based on...

The use of artificial intelligence (AI) in health care, and specifically, as the utilization of software in medical devices continues to increase. Machine learning (ML) is a branch of AI in which computer systems automatically adapt, improve, and make predictions by applying algorithms to analyze...

The use of artificial intelligence (AI) to create works of art and inventions raises interesting legal challenges to the protection of intellectual property (IP). The plain language of the Copyright Act and Patent Act present obstacles to inventors and artists who may use or be AI systems. Recent...

Kathryn Doyle, a partner at Saul Ewing, will present during the Penn Medicine Commercialization Speaker Series. She will discuss the latest trends in Life Sciences intellectual property on November 17 from 12:00 - 1:00 p.m.

Darius Gambino with Danny Cevallos - on Andy Warhol/Prince SCOTUS Case and Copyright Law in Art Danny Cevallos guest hosts the Michael Smerconish Program where he invites Saul Ewing's Darius Gambino to talk copyright law in art and music. Original air date, 14 October 2022.

Construction costs for multifamily housing rise by half In Miami-Dade County, land is very expensive and scarce along with naturally restricted boundaries, said Louis Archambault, partner for Saul Ewing. “Most of the larger tracts that would otherwise have been available if you go back a few decades...

PMG PARTNERS WITH PROP-TECH COMPANY SENTRAL TO DEVELOP DUAL-TOWER MULTIFAMILY IN BRICKELL Saul Ewing attorneys Luis Flores and Sophia Rub represented the venture in closing the acquisition of the property. “This transaction speaks to the strength of the PMG-Sentral partnership in acquiring prime...

Charles M. Lizza and Sarah A. Sullivan of Saul Ewing’s Newark Office secured a precedent-setting victory in a patent infringement case in the Federal District Court for the District of New Jersey involving Janssen Pharmaceuticals, Inc.’s (“J&J”) and Mitsubishi Tanabe Pharma Corp.’s (“MTPC”)...